February 27th, 2020
University Alumni House
https://efs.utah.edu/tms2020.php
11:30am  Lunch and Networking Opportunity
12:30pm  Welcome (Kai Kuck)
12:40pm  Opening Remarks (Andy Weyrich, University of Utah, VP of Research)
01:00pm  Keynote Address: Vicki Farrar, LightLine Medical
01:30pm  Roundtable: Translation and Innovation Resources at the U (Moderator: Satoshi Minoshima)
         Mary Albertson (TVC, Director of Commercialization)
         Willard H. Dere (Assoc. VP Research, Health Sciences; Vice Dean Research, School of Medicine)
         Wade Fallin (Orthopaedic Innovation Center, University Health)
         Bryan McRae (CMI)
         Randall Peterson (Dean, College of Pharmacy)
         Catherine Soehner (Associate Dean and Director, Eccles Health Sciences Library)
2:15pm  BREAK

02:30pm  Session I: Therapeutics (Moderator: Myles Greenberg, CEO, Alucent)
         Translational Case Study: Mei Koh, Kuda Therapeutics
         Q & A with Speakers and Panelists

3:15pm  Session II: Diagnostics (Moderator: Scott Marty, Partner, Ballard Spahr)
         Translational Case Study: Jerry Gleich, Nexeos Diagnostics
         Q & A with Speakers and Panelists

4:00pm  BREAK

4:15pm  Session III: Medical Devices (Moderator: John Zurawski, Partner, Ballard Spahr)
         Translational Case Study: Sean Runnels, Through the Cords
         Q & A with Speakers and Panelists

5:00pm - 6:30pm Networking Happy Hour (* 21 years and older only)
11:30am  Lunch and Networking Opportunity
12:30pm  Welcome (Kai Kuck)
12:40pm  Opening Remarks (Andy Weyrich, University of Utah, VP of Research)
01:00pm  Keynote Address: Vicki Farrar, LightLine Medical
01:30pm  Roundtable: Translation and Innovation Resources at the U (Moderator: Satoshi Minoshima)
        Mary Albertson (TVC, Director of Commercialization)
        Willard H. Dere (Assoc. VP Research, Health Sciences; Vice Dean Research, School of Medicine)
        Wade Fallin (Orthopaedic Innovation Center, University Health)
        Bryan McRae (CMI)
        Randall Peterson (Dean, College of Pharmacy)
        Catherine Soehner (Associate Dean and Director, Eccles Health Sciences Library)
2:15pm  BREAK
02:30pm  Session I: Therapeutics (Moderator: Myles Greenberg, CEO, Alucent)
        Translational Case Study: Mei Koh, Kuda Therapeutics
        Q & A with Speakers and Panelists
3:15pm  Session II: Diagnostics (Moderator: Scott Marty, Partner, Ballard Spahr)
        Translational Case Study: Jerry Gleich, Nexeos Diagnostics
        Q & A with Speakers and Panelists
4:00pm  BREAK
4:15pm  Session III: Medical Devices (Moderator: John Zurawski, Partner, Ballard Spahr)
        Translational Case Study: Sean Runnels, Through the Cords
        Q & A with Speakers and Panelists
5:00pm - 6:30pm Networking Happy Hour (* 21 years and older only)
**Andy Weyrich, PhD**

is the Vice President for Research at the University of Utah. He joined the University of Utah in 1993 as a postdoctoral fellow and became a research assistant professor in 1995. Weyrich was an H.A. and Edna Benning Presidential Endowed Chair while holding a position at the School of Medicine. In 2013, he received the American Society of Hematology’s Dameshek Prize. Weyrich also accepted the Investigator Recognition Award at the XXIII Congress of the International Society on Thrombosis and Hemostasis. Weyrich’s research on platelet function has been described as “hav[ing] changed our understanding of the hemostatic functions of platelets, and more importantly, the role of platelets in inflammation, infection, and angiogenesis” by ASH President Janis L. Abkowitz, MD, of the University of Washington. Weyrich continues his research efforts as the Vice President for Research, evaluating the dysregulation of molecular mechanisms in hemostatic and inflammatory systems that lead to certain disease states. Weyrich received his Ph.D. from the Bowman Gray School of Medicine in physiology and pharmacology.
Keynote Address
Vicki Farrar, JD - CEO Light Line Medical

Vicki Farrar, JD, is the CEO of Light Line Medical, a medical device company using visible light (405nm) to prevent catheter associated infections. The technology will first be used in a peritoneal dialysis catheter, followed by a urinary catheter, and then respiratory and vascular catheters. She holds over 45 years of combined experience as an attorney, intellectual property strategist, and startup CEO. Farrar moved her law practice to Utah in 1995 and began her involvement in startups in the early 2000s. Before becoming Light Line Medical’s CEO in 2017, Farrar was the original founder and CEO of Catheter Connections, a start-up specializing in medical devices to prevent hospital acquired infections. Catheter Connections was acquired by Merit Medical in 2017, which has invested in Light Line. Farrar has also served as Acting CEO and Vice President of Legal, Intellectual Property and Regulatory Affairs at Cognetix and as VP Regulatory and Intellectual Property at Q Therapeutics, Inc. in Salt Lake City. She received her law degree from Wayne State University in Detroit.
Satoshi Minoshima, MD, PhD, is Professor and Anne G. Osborn Chair in the Department of Radiology and Imaging Sciences at the University of Utah. Dr. Minoshima’s ongoing research in neuroscience utilizes molecular imaging techniques to study Alzheimer’s disease and related disorders. He is an internationally recognized leader in radiology and the peaceful use of nuclear technology in medicine. His invention of voxel-based brain image analysis and imaging database in 90’s has resulted in seminal discoveries of new Alzheimer pathology in humans. The method has become a standard practice in the field and has been distributed worldwide via industry and academic channels. He chairs the Health Sciences Research Council subcommittee on Research Entrepreneurship and Industry Partnership under Dr. Will Dere. Dr. Minoshima received his MD and PhD in radiological science from the Chiba University School of Medicine and completed a postdoctoral fellowship at the University of Michigan. He was one of the Presidential Entrepreneur Faculty Fellows at the University of Washington.
Willard Dere, MD, FACP is the Associate VP for Research (Health Sciences), Professor of Internal Medicine, and Co-Director of the University of Utah Center for Clinical and Translational Science. He worked at Eli Lilly and Amgen, over a 25 year period and led multiple drug development programs and actively participated in global regulatory affairs and pharmacovigilance programs. At Amgen Dr. Dere was head of global development and chief medical officer. He joined the University of Utah. Dr. Dere received his M.D. from the University of California, Davis, completed an internship and residency at the University of Utah in internal medicine, and obtained postdoctoral training at the University of California, San Francisco in endocrinology and metabolism.

Bryan McRae, MD, is Interim Director of the Center for Medical Innovation (CMI) and a Assistant Professor of Surgery at the University of Utah. Dr. McRae is a graduate of the University of Michigan Medical School in Ann Arbor, completed otolaryngology residency training at Indiana University and is board-certified in Otolaryngology - Head & Neck Surgery. He is also part of the Hereditary Hemorrhagic Telangiectasia surgical team at the U.'s HHT Center of Excellence. Dr. McRae has developed multiple innovative surgical devices. At CMI, he leads the medical device development programs (Bench to Bedside, Crocker Innovation Lab prototyping, etc.) and is involved in NSF I-Corps, BioVentures, and CMI Global Programs.

Randall Peterson, PhD, Dean of the College of Pharmacy and L.S. Skaggs Presidential Endowed Professor of Pharmacy at the University of Utah, joined the University of Utah in 2017 after 14 years on the faculty at Harvard University. At Harvard, Dr. Peterson was the Charles Addison and Elizabeth Ann Sanders Chair in Basic Science at the Harvard Medical School, Scientific Director of the MGH Cardiovascular Research Center, and Senior Associate Member of the Broad Institute. Dr. Peterson is a chemical biologist research utilizes high-throughput screening technologies and live zebrafish to discover new drug candidates for cardiovascular and nervous system disorders. Several of these compounds have become widely used research tools, preclinical drug candidates, and clinical-stage compounds.

Catherine Soehner, MS, is the Associate Dean for Research and Director of the Spencer S. Eccles Health Science Library at the University of Utah. Soehner began her career at the National Library of Medicine and has over 20 years of leadership experience, including directing and coordinating science and engineering libraries at the University of California Santa Cruz and the University of Michigan prior to arriving at the University of Utah in 2011. Soehner received her Master of Library Science at the Indiana University Bloomington and her Bachelor of Science in Nursing at Mount St. Joseph University.
### Session 1

**Therapeutics**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30</td>
<td>Lunch and Networking Opportunity</td>
</tr>
<tr>
<td>12:30</td>
<td>Welcome (Kai Kuck)</td>
</tr>
<tr>
<td>12:40</td>
<td>Opening Remarks (Andy Weyrich, University of Utah, VP of Research)</td>
</tr>
<tr>
<td>01:00</td>
<td>Keynote Address: Vicki Farrar, LightLine Medical</td>
</tr>
<tr>
<td>01:30</td>
<td>Roundtable: Translation and Innovation Resources at the U (Moderator: Satoshi Minoshima)</td>
</tr>
<tr>
<td></td>
<td>Mary Albertson (TVC, Director of Commercialization)</td>
</tr>
<tr>
<td></td>
<td>Willard H. Dere (Assoc. VP Research, Health Sciences; Vice Dean Research, School of Medicine)</td>
</tr>
<tr>
<td></td>
<td>Wade Fallin (Orthopaedic Innovation Center, University Health)</td>
</tr>
<tr>
<td></td>
<td>Bryan McRae (CMI)</td>
</tr>
<tr>
<td></td>
<td>Randall Peterson (Dean, College of Pharmacy)</td>
</tr>
<tr>
<td></td>
<td>Catherine Soehner (Associate Dean and Director, Eccles Health Sciences Library)</td>
</tr>
<tr>
<td>2:15</td>
<td>BREAK</td>
</tr>
<tr>
<td>02:30</td>
<td>Session I: Therapeutics (Moderator: Myles Greenberg, CEO, Alucent)</td>
</tr>
<tr>
<td></td>
<td>Translational Case Study: Mei Koh, Kuda Therapeutics</td>
</tr>
<tr>
<td></td>
<td>Q &amp; A with Speakers and Panelists</td>
</tr>
<tr>
<td>3:15</td>
<td>Session II: Diagnostics (Moderator: Scott Marty, Partner, Ballard Spahr)</td>
</tr>
<tr>
<td></td>
<td>Translational Case Study: Jerry Gleich, Nexeos Diagnostics</td>
</tr>
<tr>
<td></td>
<td>Q &amp; A with Speakers and Panelists</td>
</tr>
<tr>
<td>4:00</td>
<td>BREAK</td>
</tr>
<tr>
<td>4:15</td>
<td>Session III: Medical Devices (Moderator: John Zurawski, Partner, Ballard Spahr)</td>
</tr>
<tr>
<td></td>
<td>Translational Case Study: Sean Runnels, Through the Cords</td>
</tr>
<tr>
<td></td>
<td>Q &amp; A with Speakers and Panelists</td>
</tr>
<tr>
<td>5:00</td>
<td>6:30pm Networking Happy Hour (* 21 years and older only)</td>
</tr>
</tbody>
</table>

* * *
**Myles Greenberg, MD MBA,** is the President and CEO of Alucent Biomedical and Executive-in-Residence at the Center for Technology Venture Commercialization (TVC) at the University of Utah. Dr. Greenberg has more than 20 years of experience as a venture capital investor, entrepreneur, operating executive, board member, and clinician in the life sciences. Dr. Greenberg has spent the majority of his career as an early-stage venture capital investor, working for firms such as CHL Medical Partners, HealthInvest Equity Partners and Pappas Ventures. Dr. Greenberg often served in an interim or lead director role at the companies his firms invested in, helping lead seven companies to acquisition. Dr. Greenberg holds an M.D. from the Yale University School of Medicine and an M.B.A. from Harvard Business School.

**Sharath Hegde, PhD** is the Chief Scientific Officer at Recursion Pharmaceuticals. Dr. Hegde has over 28 years of experience in drug discovery and clinical development. He possesses extensive experience in seeding new project ideas and designing preclinical studies to test hypothesis and enable discovery of first-in-class drugs in multiple therapeutic areas including infectious, cardiovascular, respiratory, genitourinary, gastrointestinal, neurology, fibrotic, autoimmune and inflammatory diseases. Dr. Hegde spent 19 years as Theravance Biopharma where he served as the Senior Vice President for Research and 9 years at Syntex Corporation, which was later acquired by Roche. Dr. Hegde holds a Ph.D in Pharmacology from the University of Houston and his B.Pharm and M.Pharm from the University of Mumbai.

**Mei Koh, PhD,** founder/CEO of Kuda Therapeutics and Assistant Professor of Pharmacology and Toxicology at the University of Utah, has almost 20 years of experience in cancer research. She joined the University in 2017 with two R01 grants, including a $1.7 million grant to support her research investigating novel strategies to target the hypoxia-inducible factor (HIF-2) for the treatment of kidney cancer. In 2018, Kuda Therapeutics received a $300,000 SBIR for the development of novel small molecule inhibitors of HIF-2a. Dr. Koh holds a Ph.D from the University of Manchester in molecular pharmacology and did postdoctoral training at the Arizona Cancer Center. She has previously served as faculty at the University of Texas M.D. Anderson Cancer Center and at the Sanford Burnham Prebys Medical Discovery Institute.

**Ricardo Moran, PhD,** is a principal at Schwegman, Lundberg & Woesser, splitting his time between Minneapolis and San Diego. He focuses primarily on counseling clients in all aspects of intellectual property law, including pharmaceutical litigation. His technology focus is small-molecule pharmaceuticals. Ricardo holds a law degree from American University Washington College of Law, a Master's degree from Emory University, and a PhD in chemistry from the University of Maryland. He completed a post-doc at Penn State University.

**Shobha Parthasarathi, PhD,** is Xontogeny's VP of external innovation and new ventures. Before Xontogeny, Shobha was VP, Strategic Alliances and Business Development at Harrington Discovery Institute. Prior to that she was Senior Director, Business Development at the North Carolina Biotechnology Center and worked in drug discovery at Takeda Oncology (Millennium Pharmaceuticals). Shobha holds a Ph.D. in Molecular Genetics and Microbiology from Rutgers/University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School. She was Chapter Chair, Women in Bio, Research Triangle Park, serves on the External Advisory Board of University of Massachusetts Medical School’s Bridge Fund and is a mentor at The Center for Women’s Entrepreneurial Leadership at Babson College.

**Lili Portilla, MPA,** the Acting Director of Policy Communications and Strategic Alliances at the National Center for Advancing Translational Science (NCATS) has over 20 years of experience in translational science, strategic alliances, and technology transfer. She oversees NCAT’s partnership, strategic alliance and technology transfer as well as its SBIR and STTR programs. Prior to that, Portilla served as senior advisor to the director of the National Center for Research Resources, at the NIH Center for Translational Therapeutics, and as the director of the Office of Technology Transfer and Development at the National Heart, Lung and Blood Institute. Portilla holds a master’s degree in public administration from American University and a bachelor’s degree in business administration from Stephen F. Austin State University.
Session 2
DIAGNOSTICS

11:30am  Lunch and Networking Opportunity
12:30pm  Welcome (Kai Kuck)
12:40pm  Opening Remarks (Andy Weyrich, University of Utah, VP of Research)
01:00pm  Keynote Address: Vicki Farrar, LightLine Medical
01:30pm  Roundtable: Translation and Innovation Resources at the U (Moderator: Satoshi Minoshima)
                          Mary Albertson (TVC, Director of Commercialization)
                          Willard H. Dere (Assoc. VP Research, Health Sciences; Vice Dean Research, School of Medicine)
                          Wade Fallin (Orthopaedic Innovation Center, University Health)
                          Bryan McRae (CMI)
                          Randall Peterson (Dean, College of Pharmacy)
                          Catherine Soehner (Associate Dean and Director, Eccles Health Sciences Library)
2:15pm  BREAK
02:30pm  Session I: Therapeutics (Moderator: Myles Greenberg, CEO, Alucent)
                          Translational Case Study: Mei Koh, Kuda Therapeutics
                          Q & A with Speakers and Panelists
3:15pm  Session II: Diagnostics (Moderator: Scott Marty, Partner, Ballard Spahr)
                          Translational Case Study: Jerry Gleich, Nexeos Diagnostics
                          Q & A with Speakers and Panelists
4:00pm  BREAK
4:15pm  Session III: Medical Devices (Moderator: John Zurawski, Partner, Ballard Spahr)
                          Translational Case Study: Sean Runnels, Through the Cords
                          Q & A with Speakers and Panelists
5:00pm - 6:30pm Networking Happy Hour (* 21 years and older only)
Jerry Gleich, MD, a Research Professor of Dermatology and Emeritus Professor of Pediatrics at the University of Utah is Co-Founder and Chief Scientific Officer of NexEos Diagnostics. His work on eosinophil-related diseases e.g., asthma, eosinophilic esophagitis, and chronic rhinosinusitis is the basis of NexEos' novel, non-invasive imaging techniques to diagnose, assess, and guide treatment of eosinophilic esophagitis. Dr. Gleich holds an MD from the University of Michigan and is board-certified in Allergy, Immunology, and Internal Medicine. He has served as Chairman of the WHO Subcommittee on Standardization of Allergens, on the Allergy and Clinical Immunology Research Committee of the National Institute of Allergy and Infectious Diseases (NIAID), and as Chairman of NIAID's Board of Scientific Counselors.

Noriko Kusukawa, PhD, is the Vice President and Director of Innovation and Strategic Investments at ARUP Laboratories and an Adjunct Associate Professor of Pathology at the University of Utah. Dr. Kusukawa has more than 20 years of business development experience. Prior to her position at ARUP, Dr. Kusukawa was a technical director of FMC Corporation, overseeing the Research and Development and Compliance and Quality Systems departments. Dr. Kusukawa specializes in industry collaborations and in-licensing, allowing ARUP to stay at the forefront of pathology specimen processing, handling, and testing. Dr. Kusukawa received her PhD from Kyoto University in Japan.

Scott Marty, PhD, JD, is a Partner at Ballard Spahr, LLP, where he leads the Patent Group’s biotechnology practice team. Marty offers over 15 years of patent prosecution and litigation experience, specializing in biotechnology and pharmaceuticals. Marty’s expertise in prosecution was recognized in 2014, 2015, and 2019 as he was listed among the IAM Patent 1000’s leading patent professionals. He was also named as a Georgia Super Lawyer – Rising Star in 2013. Marty obtained his Ph.D. from the Medical College of Georgia in biochemistry and molecular biology and his J.D. from the Georgia State University College of Law.

Andy Olson, MBA, Co-Founder and CEO of Inherent Biosciences and Entrepreneur-in-Residence at the University of Utah's TVC, has over 15 years of experience commercializing biotechnologies for both startups and large enterprises. He specializes in molecular diagnostics markets—specifically genetics, infectious diseases, and cancer. Olson has previously held positions as Product Manager of BD GeneOhm Sciences, Vice President of Sales and Marketing for Signature Genomics, and Chief Operating Officer of Tute Genomics. As CEO of Inherent Biosciences, Olson is pursuing the distribution of proprietary DNA tests to precisely diagnose the cause of consumers’ chronic diseases. Olson obtained his M.B.A. from the University of Houston C.T. Bauer College of Business.

John B. Wirthlin, MBA, is the CEO of Lumea, which he joined in 2015. He has more than fifteen years of experience starting and growing innovative life science companies, including AlloCure Inc. and Echelon Biosciences Inc. His experience includes: fund raising, strategic leadership, team building, intellectual property portfolio management, business and corporate development, GMP manufacturing, biologics, cell therapy development, finance, clinical development, regulatory, technology transfer, licensing, leading cross functional teams, and creating value for investors. Mr. Wirthlin earned an MBA from Westminster College with an emphasis on technology commercialization.
Session 3
MEDICAL DEVICES

11:30am  Lunch and Networking Opportunity
12:30pm  Welcome (Kai Kuck)
12:40pm  Opening Remarks (Andy Weyrich, University of Utah, VP of Research)
01:00pm  Keynote Address: Vicki Farrar, LightLine Medical
01:30pm  Roundtable: Translation and Innovation Resources at the U (Moderator: Satoshi Minoshima)
          Mary Albertson (TVC, Director of Commercialization)
          Willard H. Dere (Assoc. VP Research, Health Sciences; Vice Dean Research, School of Medicine)
          Wade Fallin (Orthopaedic Innovation Center, University Health)
          Bryan McRae (CMI)
          Randall Peterson (Dean, College of Pharmacy)
          Catherine Soehner (Associate Dean and Director, Eccles Health Sciences Library)
2:15pm  BREAK
02:30pm  Session I: Therapeutics (Moderator: Myles Greenberg, CEO, Alucent)
          Translational Case Study: Mei Koh, Kuda Therapeutics
          Q & A with Speakers and Panelists
3:15pm  Session II: Diagnostics (Moderator: Scott Marty, Partner, Ballard Spahr)
          Translational Case Study: Jerry Gleich, Nexeos Diagnostics
          Q & A with Speakers and Panelists
4:00pm  BREAK

4:15pm  Session III: Medical Devices (Moderator: John Zurawski, Partner, Ballard Spahr)
          Translational Case Study: Sean Runnels, Through the Cords
          Q & A with Speakers and Panelists
5:00pm - 6:30pm Networking Happy Hour (* 21 years and older only)
Session 3 -- Medical Devices

Marcia Griffiths, MBA, is the President and CEO of Rocky Mountain Research, a small medical device firm. She has over 25 years of experience in all aspects of running a medical device company, including sales, marketing, compliance, manufacturing, and business development. Before becoming CEO of Rocky Mountain Research, Griffiths serves as CFO and Regulatory Affairs and Quality Assurance Director. Her key areas of expertise include new product development, regulatory management, and quality systems. Griffiths obtained her Executive M.B.A. from the University of Utah David Eccles School of Business.

Branden Rosenhan, MD, Managing Director of MedMountain Ventures and Co-Founder of SimplicityMD, has extensive experience in the development and launch of medical devices. His focus is on identifying disruptive healthcare solutions that improve patient care and reduce costs. Dr. Rosenhan started his career as a critical care physician and has over ten years of experience as an entrepreneur, executive, and board member. Dr. Rosenhan obtained his MD from the University of Utah School of Medicine and his BS in Bioengineering from Arizona State University. Dr. Rosenhan is a board certified physician in Internal Medicine and Critical Care Medicine.

Shawn Fojtik, MA, is the President and Co-Founder of Control Medical Technology and Distal Access and an Adjunct Assistant Professor of Surgery at the University of Utah. Fojtik has nearly 20 years of experience as a startup executive, having served as the president of Pinyons Medical Technology - which was acquired by Covidien, the president of RESECTOR - which was acquired by Boston Scientific, and as the president of SPINR - which was acquired by Merit Medical. Fojtik has over 100 issued and pending patent applications to his name, highlighting the depth of his experience in the medical device industry. Fojtik received his M.A at Harvard University.

Sean Runnels, MD, is the Founder and CEO of Through the Cords and a Clinical Associate Professor of Anesthesiology at the University of Utah. Dr. Runnels was fellowship trained as a cardiothoracic anesthesiologist at Cambridge University in the UK and has extensive experience in difficult airway management. In 2015, he returned to the University of Utah after a three-year sabbatical teaching in Africa. He spent one year in Guinea on the surgical hospital ship Africa Mercy, and two years as faculty at the National University of Rwanda, which inspired him to develop and commercialize a system that enables flexible, safe, and easy-to-master intubation despite difficult airways – the focus of Through the Cords. Dr. Runnels obtained his M.D. from the Oregon Health Sciences University Medical School.

Craig Watson, BS, is the Vice President of National Accounts for the Medical Device Contract Manufacturing division at Medline Industries. He and his team partner with Medical Device Manufacturers to help their product launch faster, more efficiently, and at a lower total cost. Medline is the largest privately held manufacturer and distributor of medical supplies with $13.9 billion in revenue in 2019. Watson has over 10 years of experience at Medline and nearly 20 years of experience as a businessman, deal maker, and innovator. Watson received his Bachelor of Business Administration degree in marketing and accounting from Oklahoma State University.

John A. Zurawski, JD, M Biotech, is a Partner at Ballard Spahr, LLP, where he serves as a licensed patent attorney, focusing on intellectual property issues as well as commercial contract drafting and negotiation. He works with universities, emerging growth companies, and entrepreneurs, including pharmaceutical companies and large equipment and vehicle manufacturer throughout their commercial lifecycles starting as early as formation and also represents them in preclinical and clinical development. He was named a Pennsylvania Super Lawyer – Rising Star in 2010, 2013, 2015, 2016, and 2017. Zurawski holds a M.Biotech (concentration: Molecular Biology) from the University of Pennsylvania and a J.D. from Villanova University School of Law.